Determination of measurement uncertainty for the determination of triazines in groundwater from validation data

The Analyst ◽  
2001 ◽  
Vol 126 (2) ◽  
pp. 211-216 ◽  
Author(s):  
Thomas P. J. Linsinger ◽  
Manuela Führer ◽  
Wolfgang Kandler ◽  
Rainer Schuhmacher

Talanta ◽  
2020 ◽  
Vol 220 ◽  
pp. 121386 ◽  
Author(s):  
David Milde ◽  
Tomáš Pluháček ◽  
Martin Kuba ◽  
Jitka Součková ◽  
Ricardo J.N. Bettencourt da Silva




2012 ◽  
Vol 95 (4) ◽  
pp. 933-936 ◽  
Author(s):  
Ursula Kirchner ◽  
Katharina Degenhardt ◽  
Guenther Raffler ◽  
Maria Nelson

Abstract During the “Standards Development and International Harmonization: AOAC INTERNATIONAL Mid-Year Meeting,” on June 29, 2011, the method “Determination of Vitamin B12 in Infant Formula and Adult Nutritionals Using HPLC After Purification on an Immunoaffinity Column” was recommended by an Expert Review Panel and adopted as AOAC Official First Action status. The method is applicable for the determination of vitamin B12 in milk-based infant formula. Vitamin B12 is extracted from the sample in sodium acetate buffer in the presence of potassium cyanide. After purification and concentration with an immunoaffinity column (IAC), vitamin B12 is determined by LC with UV detection (361 nm). Data supplied by CLF demonstrated linear response over a wide range of concentrations (1.4–39 μg/100 mL). The analytical range is 0.2–10 μg/100 g, depending on the capacity of the IACs (0.01–0.5 μg), the input weight, and dilutions. Recovery rates were assessed using National Institute of Standards and Technology SRM 1849, and determined to be 95.1%, with SD of 0.34 and CV of 9.0. Measurement uncertainty (UE) was 0.8 μg/100 g, which was calculated from the validation data. It is an expanded measurement uncertainty and was obtained through multiplication with a coverage factor k. LOQ values were reported as 0.10 μg/100 g. The performance characteristics of the method met the standard method performance requirements set forth by the AOAC Stakeholder Panel on Infant Formula and Adult Nutritionals; thus, the method was determined to be appropriate for First Action status.



Talanta ◽  
2021 ◽  
Vol 232 ◽  
pp. 122286
Author(s):  
María Melania Ramírez-Quesada ◽  
Jimmy Venegas-Padilla ◽  
José Pablo Sibaja-Brenes ◽  
Bryan Calderón-Jiménez


Author(s):  
Klaus Brun ◽  
Rainer Kurz

Field testing of gas turbine compressor packages requires the accurate determination of efficiency, capacity, head, power and fuel flow in sometimes less than ideal working environments. Nonetheless, field test results have significant implication for the compressor and gas turbine manufacturers and their customers. Economic considerations demand that the performance and efficiency of an installation are verified to assure a project’s return on investment. Thus, for the compressor and gas turbine manufacturers, as well as for the end-user, an accurate determination of the field performance is of vital interest. This paper describes an analytic method to predict the measurement uncertainty and, thus, the accuracy, of field test results for gas turbine driven compressors. Namely, a method is presented which can be employed to verify the validity of field test performance results. The equations governing the compressor and gas turbine performance uncertainties are rigorously derived and results are numerically compared to actual field test data. Typical field test measurement uncertainties are presented for different sets of instrumentation. Test parameters that correlate to the most significant influence on the performance uncertainties are identified and suggestions are provided on how to minimize their measurement errors. The effect of different equations of state on the calculated performance is also discussed. Results show that compressor efficiency uncertainties can be unacceptably high when some basic rules for accurate testing are violated. However, by following some simple measurement rules and maintaining commonality of the gas equations of state, the overall compressor package performance measurement uncertainty can be limited and meaningful results can be achieved.





2018 ◽  
Vol 23 (4) ◽  
pp. 243-250 ◽  
Author(s):  
Marijana Kragulj Isakovski ◽  
Jelena Molnar Jazić ◽  
Snežana Maletić ◽  
Aleksandra Tubić ◽  
Jasmina Agbaba ◽  
...  


Author(s):  
S. Senthil Kumar ◽  
Ritesh Kumar Srivastava ◽  
V. Srinivas Rao

<p><strong>Objective: </strong>The objective of present study was to develop and validate a specific and sensitive HPLC method for the quantitative determination of genotoxic impurity 2-cyano-4’-bromomethyl biphenyl present in irbesartan drug substance.</p><p><strong>Methods: </strong>The development activity was conducted by HPLC with UV as a detector. The impurity was separated on Kromasil C18 250 x 4.6 mm, 5 µm analytical column with a mobile phase consisting of buffer pH 3.2 and acetonitrile in the ratio of 60:40 v/v at a flow rate 1.5 ml/min. The effluent was monitored by UV detection at 258 nm with column temperature maintained at 40 °C and the injection volume 30 μl. Acetonitrile was selected as diluent.</p><p><strong>Results: </strong>Validation activity was planned and completed based on the ICH guideline. The LOD and LOQ value were found to be 0.167 µg/g and 0.506 µg/g and accuracy results were well in the range 98.34 to 103.46 %. The linearity curve showed the correlation coefficient of 0.9999 and method very sensitive.</p><p><strong>Conclusion: </strong>From validation data, it was confirmed that the developed method is specific, sensitive, linear, precise and accurate for the determination of 2-cyano-4’-bromomethyl biphenyl genotoxic impurity in irbesartan drug substances.</p>



Sign in / Sign up

Export Citation Format

Share Document